US$ 24.23
off-label use of glp-1 agonists for obesity in 2016 GLP1 Receptor Agonists—Effects beyond and Diabetes Pharmacologic treatment of obesity in
Description
[DOI] [PubMed] [Google Scholar] 150.Bezin J., et al

GLP-1 agonists affect fetal weight, growth and skeletal ossification in animal studies, although liraglutide and exenatide do not cross the placenta

Please note that any medication or lab work costs are not included

In 2010, the Danish company Novo Nordisk received regulatory approval for their drug liraglutide

2024 Sep 18;9(1):234

However, sensitivity analyses excluding this study did not materially alter pooled estimates, supporting the robustness of the findings
